AbbVie reported $62.48B in Loan Capital for its fiscal quarter ending in June of 2026.





Loan Capital Change Date
AbbVie USD 62.48B 2.05B Jun/2026
Abbott USD 29.45B 152M Sep/2026
ALKERMES USD 1.47B 5.38M Sep/2026
Amgen USD 51.61B 250M Sep/2026
AstraZeneca USD 28.8B 2.79B Sep/2026
Biogen USD 7.29B 1.7M Sep/2026
BioMarin Pharmaceutical USD 3.51B 12.96M Sep/2026
Bristol-Myers Squibb USD 41.85B 244M Sep/2026
Coherus Biosciences USD 51.08M 496K Dec/2025
Eisai JPY 184.62B 19M Sep/2026
Eli Lilly USD 46.99B 872M Sep/2026
Gilead Sciences USD 23.82B 17M Sep/2026
GlaxoSmithKline GBP 21.7B 7.75B Sep/2026
J&J USD 35.8B 1.55B Sep/2026
Medtronic USD 25.62B 502M Jun/2026
Merck USD 49.69B 1.39B Sep/2026
Neurocrine Biosciences USD 169.5M 500K Mar/2023
Novartis USD 38.38B 893M Sep/2026
Perrigo USD 3.28B 600K Sep/2026
Pfizer USD 60B 498M Sep/2026
Regeneron Pharmaceuticals USD 1.99B 400K Sep/2026
Roche Holding CHF 25.22B 2.21B Jun/2026
Sanofi EUR 16.28B 1.63B Sep/2026
UCB EUR 2.18B 634M Dec/2025
Ultragenyx Pharmaceutical USD 1.13B 2M Jun/2026
United Therapeutics USD 100M 100M Jun/2024
Vertex Pharmaceuticals USD 3.5B 3.39B Sep/2026
Zoetis USD 8.3B 749M Sep/2026